220 completed, 84 recruiting, 61 unknown, 38 terminated. 154 Phase 2, 111 Not applicable, 84 Phase 1, 27 Phase 3, 8 Phase 4.
Follow Nerve Sheath Neoplasms: new trials by email Literature Review of Nerve Sheath Neoplasms trials Research Report on Nerve Sheath Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs) GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling) - Neurofibromatosis 1 (NF1), Neurofibromatosis Type I | Not applicable | Suspended | Massachusetts General Hospital | 10 | 2027-01-01 | 2026-06-04 |
| Role of ChatGPT in Vestibular Schwannoma Management Use of chatGPT for 1 week - Vestibular Schwannoma | Not applicable | Withdrawn | University of Southern California | 2027-01-01 | 2026-01-13 | |
| Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma mirdametinib with radiation, mirdametinib - Neurofibromatosis 1 (NF1) | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 55 | 2027-01-01 | 2026-10-05 |
| Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor) | Phase 2 | Not yet recruiting | Girish Dhall, MD | 25 | 2027-01-01 | 2026-10-28 |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| Comparative Evaluation of Intraneuroma and Perineuroma Botulinum Toxin Type A Injection Techniques for Chronic Neuroma Pain After Combat-Related Amputation Botulinum toxin type A injection - Chronic Pain, Neuroma | Not applicable | Completed | Ukrainian Society of Regional Anesthesia and Pain Therapy | 100 | 2026-10-01 | 2026-10-06 |
| Cognitive Intervention for Children and Adolescents With NF1 Unstuck and On Target! - Neurofibromatosis 1 (NF1), Executive Function (Cognition) | Not applicable | Not yet recruiting | The Hospital for Sick Children | 60 | 2026-09-28 | 2026-10-13 |
| Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN) Neurofibromatosis Type 1 (NF1) | Recruiting | AstraZeneca | 800 | 2026-09-28 | 2026-10-22 | |
| Neurocutaneous Syndromes in Children: Prevalence and Clinical Characteristics Sturge-Weber Syndrome, Neurocutaneous Syndromes | Not yet recruiting | Assiut University | 100 | 2026-09-20 | 2026-09-28 | |
| Ultrasound-Guided Platelet-Rich Plasma Versus Local Anesthetic Injection for Chronic Neuroma Pain After Combat-Related Amputation Platelet-Rich Plasma (PRP) Injections, Local Anesthetic Injection - Neuroma, Phantom Limb Pain After Amputation | Not applicable | Completed | Ukrainian Society of Regional Anesthesia and Pain Therapy | 100 | 2026-09-15 | 2026-10-07 |
| How Can the Experience of Hospital Outpatient Departments be Improved? Qualitative data collection activities - Neurofibromatosis Type 1 (NF1), NF2-related Schwannomatosis | Not yet recruiting | King's College London | 30 | 2026-09-01 | 2026-09-14 | |
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1 | Phase 2 | Recruiting | University of Alabama at Birmingham | 41 | 2026-08-04 | 2026-08-24 |
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 1 / Phase 2 | Recruiting | Ankit Mangla, MD | 17 | 2026-08-01 | 2026-08-11 |
| Gait in Young Children With NF1 Neurofibromatosis Type 1 | Not yet recruiting | NYU Langone Health | 56 | 2026-08-01 | 2026-05-08 | |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures Panitumumab-IRDye800 - Meningioma, Glioblastoma | Early Phase 1 | Recruiting | Eben Rosenthal | 30 | 2026-07-07 | 2026-10-16 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 40 | 2026-06-15 | 2026-10-01 |
| Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 | Recruiting | Girish Dhall, MD | 30 | 2026-06-09 | 2026-10-02 |
Showing 20 of 487. Sign in to see all of them.
Neurofibromatosis 1 (174) · Neuroma, Acoustic (98) · Neurofibrosarcoma (97) · Sarcoma (68) · Neurofibroma, Plexiform (62) · Neurofibromatoses (57) · Sarcoma, Synovial (48) · Neurofibromatosis 2 (47) · Leiomyosarcoma (46) · Neuroma (46) · Histiocytoma, Malignant Fibrous (41) · Liposarcoma (40) · Fibrosarcoma (38) · Hemangiosarcoma (35) · Rhabdomyosarcoma (32)
Neoplasms by Histologic Type (487) · Neoplasms, Nerve Tissue (486) · Neoplasms (471) · Nervous System Diseases (455) · Neurofibroma (315) · Neuromuscular Diseases (312) · Peripheral Nervous System Diseases (307) · Nervous System Neoplasms (298) · Peripheral Nervous System Neoplasms (282) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (260) · Neoplastic Syndromes, Hereditary (254) · Genetic Diseases, Inborn (253) · Neurodegenerative Diseases (246) · Heredodegenerative Disorders, Nervous System (245)
AZD 6244 (23) · Doxorubicin (17) · Ifosfamide (12) · Bevacizumab (8) · Radiotherapy (8) · Everolimus (7) · Imatinib Mesylate (7) · Radiosurgery (7) · Sirolimus (7) · Magnetic Resonance Spectroscopy (6) · trametinib (6) · Lovastatin (5) · mirdametinib (5) · pazopanib (5) · Cochlear Implants (4)
National Cancer Institute (NCI) (50) · Massachusetts General Hospital (21) · AstraZeneca (15) · European Organisation for Research and Treatment of Cancer - EORTC (13) · University of Alabama at Birmingham (10) · Memorial Sloan Kettering Cancer Center (8) · Washington University School of Medicine (8) · Assistance Publique - Hôpitaux de Paris (6) · Massachusetts Eye and Ear Infirmary (6) · Medical University of Vienna (6) · NYU Langone Health (6) · Novartis Pharmaceuticals (6) · University Hospital, Strasbourg, France (6) · Beijing Tiantan Hospital (5) · Northwestern University (5)
United States (282) · France (47) · China (32) · United Kingdom (31) · Germany (21) · Canada (19) · Netherlands (19) · Belgium (14) · Spain (14) · Denmark (12) · Austria (11) · Italy (10) · Australia (9) · Japan (7) · Poland (7)
Brigitte C Widemann, M.D. (13) · Staci M Peron, Ph.D. (7) · Ana-Maria Vranceanu, PhD (5) · Girish Dhall, MD (4) · AeRang Kim, MD, PhD (3) · Brigitte C. Widemann, MD (3) · Jason R Fangusaro (3) · Matthias A Karajannis, MD, MS (3) · Pamela L Wolters, Ph.D. (3) · Pinan Liu (3) · Richard R Anderson, MD (3) · Scott Plotkin, MD (3) · Scott Plotkin, MD, PhD (3) · Vanessa Merker, PhD (3)
PMID 28029918, PMID 32187457, PMID 15683544, PMID 17105749, PMID 17917842, PMID 19574236, PMID 19645909, PMID 21996156, PMID 22027076, PMID 22353803, PMID 26851632, PMID 28230061, PMID 28409229, PMID 31010905, PMID 31401903, PMID 31582003, PMID 33354735, PMID 33863389, PMID 34541874, PMID 35007270, PMID 38908005, PMID 10449559, PMID 11587600, PMID 11705489, PMID 11710496, PMID 11981398, PMID 12528778, PMID 12925338, PMID 12943357, PMID 12957454, PMID 14724495, PMID 15010069, PMID 15177491, PMID 15354006, PMID 15519876, PMID 15592836, PMID 15613856, PMID 15659504, PMID 16046979, PMID 16528479, PMID 16877612, PMID 16996566, PMID 17095209, PMID 17336054, PMID 17438254, PMID 17562049, PMID 17634494, PMID 18607963, PMID 18758957, PMID 18769654
U10CA180886 (5), P30CA008748 (4), U10CA098543 (3), 2018 (2), N01CM62206 (2), U01CA069856 (2), U10CA180821 (2), UM1CA081457 (2), 2009 (1), 2016 (1), 2017 (1), 2023 (1), K08CA245181 (1), K23NS146694 (1), N01CM00071 (1)